GlassScriptPhysician profile
Lisa A Davis
NPI 1457632176
$4,767.03
in general payments reported to CMS, 2019-2025
32 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $973 · 2022: $399 · 2023: $977 · 2024: $1,255 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,394.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $526.06 | 2021-2024 | Xarelto |
| Atricure, INC. | $523.22 | 2023-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Novartis Pharmaceuticals Corporation | $493.73 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $387.03 | 2021-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $313.17 | 2021-2023 | Watchman |
| Esperion Therapeutics, INC. | $274.98 | 2021-2025 | Nexletol |
| Pfizer INC. | $260.24 | 2021-2025 | |
| Amgen INC. | $229.16 | 2021-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $220.85 | 2023-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $213.50 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $174.13 | 2022-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $126.98 | 2024-2025 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $125.72 | 2021-2025 | Farxiga |
| Novo Nordisk INC | $105.10 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $103.36 | 2023-2025 | Evkeeza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $100.13 | 2024 | Optimizer |
| Daiichi Sankyo INC. | $67.98 | 2023 | Injectafer |
| Altathera Pharmaceuticals LLC | $59.57 | 2023-2025 | Sotalol Hydrochloride |
| Kiniksa Pharmaceuticals International, Plc | $51.33 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $46.77 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.02 | 2021-2023 | Jardiance |
| Vifor Pharma, INC. | $44.45 | 2021 | |
| Cleerly, INC. | $41.48 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Bayer Healthcare Pharmaceuticals INC. | $39.32 | 2025 | |
| Cvrx, INC. | $35.65 | 2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $32.66 | 2023 | Inpefa |
| Sanofi-Aventis U.S. LLC | $29.43 | 2023 | |
| Inspire Medical Systems, INC. | $24.25 | 2023 | Inspire |
| Abiomed | $23.43 | 2025 | |
| Xeris Pharmaceuticals, INC. | $18.96 | 2025 | Keveyis |
| Medtronic, INC. | $15.74 | 2022 | |
| Bridgebio Pharma, INC. | $13.63 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.